Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547000 · ClinicalTrials.gov registry record · Phase 4
Guanfacine in Children With Tic Disorders
A Phase 4 study of Tourette Syndrome and Tourette Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 3
- Study locations
NCT01547000: Completed Phase 4 study of Tourette Syndrome and Tourette Disorder, sponsored by Yale University.
NCT01547000 is a Phase 4 study of Tourette Syndrome and Tourette Disorder that has completed, run by Yale University. The registered enrollment target is 34 participants, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (60% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01547000, a Phase 4 study of Tourette Syndrome and Tourette Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this pilot study is to obtain preliminary information on the tolerability and efficacy of extended release guanfacine (trade name Intuniv) in children with Tourette Disorder (TD, also called Tourette syndrome).
Primary Outcome
The YGTSS is a clinician-rated scale that begins with a systematic inquiry of tic symptoms in the preceding week. Current motor and phonic tics are rated separately according to number, frequency, intensity, complexity, and interference, each rated on 0 to 5 scale with higher scores indicating greater severity/worse outcome (Leckman et al. 1989). The YGTSS yields a total motor score (0-25), a total phonic score (0-25), a total tic score (sum of total motor and total phonic scores; 0-50), and an
Conditions Studied
Interventions
- DRUG placebo
- DRUG extended-release guanfacine (Intuniv)
Study Locations (3)
Connecticut
- Yale Child Study Center - New Haven
Florida
- University of South Florida - Tampa
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-04 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
What the finished NCT01547000 record still lists
NCT01547000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Tourette Syndrome appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01547000 reports a single indexed study location in Connecticut, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01547000 about?
NCT01547000 is a clinical study titled "Guanfacine in Children With Tic Disorders". The goal of this pilot study is to obtain preliminary information on the tolerability and efficacy of extended release guanfacine (trade name Intuniv) in children with Tourette Disorder (TD, also called Tourette syndrome).
What is the current status of trial NCT01547000?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2012-04. Estimated completion is 2016-12.
What conditions does trial NCT01547000 study?
This clinical trial studies the following conditions: Tourette Syndrome, Tourette Disorder.
What interventions are being tested in trial NCT01547000?
The interventions under investigation include: placebo (DRUG), extended-release guanfacine (Intuniv) (DRUG).
Who is sponsoring clinical trial NCT01547000?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01547000 being conducted?
This trial has 3 study locations across Connecticut, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01547000's enrollment target sits among peer trials
34 22nd of 33 higher than 12 of 33 other Tourette Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tourette Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
COMPLETED · Phase 4
-
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
RECRUITING
-
Remote Delivery of a Mindfulness-based Intervention for Tics
RECRUITING · NA
-
Sensory Symptoms in Tourette Syndrome
RECRUITING
-
Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics
RECRUITING · Phase 2
-
Trajectories of Change in Tourette Syndrome
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia